Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).
Scarisbrick, J Dwyer, K Leoni, M Grebennik, D Morris, S
Scarisbrick, J
Dwyer, K
Leoni, M
Grebennik, D
Morris, S
Citations
Altmetric:
Abstract
Affiliation
Description
Lymphoma Research Team
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). 2018, 181: 77-78 BR J Haematol